Research programme: transforming growth factor beta receptor kinase inhibitors - Bristol-Myers Squibb/RigelAlternative Names: TGF beta receptor kinase inhibitors - Bristol-Myers Squibb/Rigel
Latest Information Update: 18 Mar 2015
At a glance
- Originator Rigel Pharmaceuticals
- Developer Bristol-Myers Squibb; Rigel Pharmaceuticals
- Class Small molecules
- Mechanism of Action TGF-beta superfamily protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer